middle.news
CSL Boosts Profit 6% with Strong Plasma Sales, Faces Vaccine Market Headwinds
8:10am on Tuesday 11th of February, 2025 AEDT
•
Pharmaceuticals
Read Story
CSL Boosts Profit 6% with Strong Plasma Sales, Faces Vaccine Market Headwinds
8:10am on Tuesday 11th of February, 2025 AEDT
Key Points
Total revenue up 5% to US$8.48 billion
Net profit after tax (NPAT) rises 6% to US$2.01 billion
CSL Behring revenue grows 10%, driven by immunoglobulin and haemophilia products
CSL Seqirus revenue declines 9% due to low influenza immunisation rates
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
CSL (ASX:CSL)
OPEN ARTICLE